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Abstract
Background: In vitro pharmacology of ligands is typically assessed using a variety of molecular assays based on
predetermined molecular events in living cells. Many ligands including opioid ligands pose the ability to bind more
than one receptor, and can also provide distinct operational bias to activate a specific receptor. Generating an
integrative overview of the binding and functional selectivity of ligands for a receptor family is a critical but difficult
step in drug discovery and development. Here we applied a newly developed label-free integrative pharmacology
on-target (iPOT) approach to systematically survey the selectivity of a library of fifty-five opioid ligands against the
opioid receptor family. All ligands were interrogated using dynamic mass redistribution (DMR) assays in both
recombinant and native cell lines that express specific opioid receptor(s). The cells were modified with a set of
probe molecules to manifest the binding and functional selectivity of ligands. DMR profiles were collected and
translated to numerical coordinates that was subject to similarity analysis. A specific set of opioid ligands were then
selected for quantitative pharmacology determination.
Results: Results showed that among fifty-five opioid ligands examined most ligands displayed agonist activity in at
least one opioid receptor expressing cell line under different conditions. Further, many ligands exhibited pathway
biased agonism.
Conclusion: We demonstrate that the iPOT effectively sorts the ligands into distinct clusters based on their binding
and functional selectivity at the opioid receptor family.
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Background
Historically, drug selectivity is described as the differential
binding affinity of drug molecules to distinct receptors.
The discovery of ligand-directed functional selectivity or
biased agonism has led to new avenues for achieving de-
sired drug selectivity. Functional selectivity describes the
differential ability of drug molecules to activate one of the
multiple downstream pathways to which the receptor is
coupled [1-4]. Opioid receptors exemplify many aspects of
functional selectivity, with the dependency of receptor-
mediated events on ligands used and the cellular or
in vivo environments examined [5]. Functional selectivity
of opioid drugs has been postulated to be related to their
clinical profiles, particularly the progression of analgesic
tolerance after their extended use [6].
However, integrating functional selectivity into the
drug development process remains a challenging prob-
lem. The wide spectrum of signaling events mediated by
a receptor [7], coupled with the differences in signaling
components in distinct types of cells [8], makes it ex-
tremely difficult to fully discover and quantify the func-
tional selectivity of drug molecules using conventional
molecular assays. Also, these molecular assays screen
drug molecules based on a predetermined molecular hy-
pothesis, but such a hypothesis may or may not be rele-
vant to the pathogenesis of a disease [9]. A further
complication is the existence of signaling readout- and
cell background-dependent potency and efficacy, which
is inherited from the operational bias of drug molecules
on a receptor [3]. The possibility that a drug may have
multidimensional efficacy makes it difficult to optimize
and prioritize drug candidate molecules. In many in-
stances, the efficacy profiles obtained for a candidate
drug may not be good predictors of their in vivo
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therapeutic impacts, and it may be difficult to sort out
which molecular mode of action leads to a desired thera-
peutic impact. Thus, assays that are phenotypic in nature
yet allow mechanistic descriptions of drug actions would
be advantageous.
With the ability to interrogate wide pathway coverage
utilizing a single assay and to mechanistically delineate
drug pharmacology at the whole cell or cell system level,
label-free receptor assays have emerged as promising
platforms for drug discovery [10-14]. Here, we applied a
recently developed label-free integrative pharmacology
on-target (iPOT) approach [15,16] to systematically sur-
vey the binding and functional selectivity of a library of
opioid ligands. This comparative pharmacological ap-
proach is centered on similarity analysis of DMR profiles
of drugs obtained in model cell lines that have been
pretreated with a wide variety of probe chemicals. The
probe molecules are chosen to modify pathways down-
stream of activated receptors, so that the sensitivity of
drugs to the pathway modulation can be surveyed at the
whole cell level. After translating DMR profiles into
multidimensional coordinates, similarity analysis is used
to categorize drugs into distinct clusters. We found that
the iPOT approach provides an integrative display of the
binding and functional selectivity of a library of opioid
ligands at the family of opioid receptors.
Methods
Materials and reagents
Pertussis toxin (PTX), cholera toxin (CTX), forskolin and
dimethyl sulfoxide (DMSO) were purchased from Sigma-
Aldrich (St. Louis, MO). DAMGO, DPDPE, BRL-52537,
CTOP, naltrindole hydrochloride, norbinaltorphimine,
U0126, SB202190, SP600125, and LY294002 were pur-
chased from Tocris Biosciences (Ellisville, MO). The Opi-
oid Compound Library consisting of 64 compounds of
pan-specific and receptor subtype-specific agonists and
antagonists, each at 10 mM in DMSO, was obtained from
Enzo Life Sciences (Plymouth Meeting, PA). All tissue cul-
ture media and reagents were purchased from Invitrogen
(Calrsbad, CA). Both fibronectin-coated and tissue culture
treated (TCT) EpicW biosensor microplates, as well as
polypropylene compound source plates were obtained
from Corning Inc (Corning, NY).
Cell culture
We used five distinct cell lines including human neuro-
blastoma cell line SH-SY5Y, human embryonic kidney
HEK293 cells, and three engineered HEK 293 cell lines
for label-free pharmacology profiling. HEK293 cells and
SH-SY5Y cells were obtained from American Type Tissue
Culture (Manassas, VA) and cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM GlutaMAX-I) supplemented
with 10% non-heated inactivated fetal bovine serum, 100
units/ml penicillin, and 100 g/ml streptomycin. Both
HEK-MOR and HEK-DOR cell lines were a generous gift
from Dr. Mark von Zastrow (University of California, San
Francisco). The HEK-KOR cell line was donated from Dr.
Lee-Yuen Lui-Chen (Temple University).
The HEK-MOR stably expresses FLAG-tagged wild
type human mu opioid receptor (MOR1) with a Bmax of
2.5 pmoles/mg cell protein [16,17]. The HEK-DOR sta-
bly expresses FLAG-tagged wild type human delta opi-
oid receptor with a Bmax of 0.8 pmoles/mg cell protein
[18]. The HEK-KOR cell line stably expresses FLAG-
tagged wild type human kappa opioid receptor with an
unknown Bmax [19]. SH-SY5Y is a dopaminergic neur-
onal cell line which has been used as an in vitro model
for assessment of functional responses of the MOR. SH-
SY5Y is known to express both MOR and DOR with a
protein ratio of approximately 4.5:1 [20], and the Bmax
for the DOR was estimated to be 35 to 100 fmol/mg
protein [21,22]. SH-SH5Y is also known to endogenously
express several splice variants of opioid receptors includ-
ing a single TM protein (MOR1S) resulting from an
exon-skipping variant [23,24], an alternatively spliced
isoform MOR1K that is a 6TM GPCR variant without
the N-terminal extracellular and first transmembrane
domains and is preferentially coupled to Gαs [25], and a
splice variant of δ opioid receptor that lacks the third
cytoplasmic loop of the native receptor [26]. This short δ
receptor appeared to be associated with human malignoma,
although its biological functions remain unknown.
These cells were grown in complete DMEM GlutaMAX-
I containing 400 μg/ml geneticin. For cell culture in the
fibronectin-coated EpicW biosensor microplates, cells were
seeded at a density of 16,000 cells/40 μL/well for HEK293
cells, and 20,000 cells/40 μL/well for both HEK-DOR and
HEK-KOR cells. For SH-SY5Y cells, cells were seeded at
15,000 cells/40 μL/well onto EpicW tissue culture compat-
ible microplates. After seeding the biosensor microplates
were incubated for 30 min at room temperature, and then
transferred to a humidified incubator (37°C, 5% CO2) for
20–24 hrs for HEK cells, or 48 hours for SH-SY5Y cells.
Dynamic mass redistribution (DMR) assays
DMR assays were performed using EpicW system as pre-
viously described [27]. EpicW system from Corning is a
wavelength interrogation reader system tailored for res-
onant waveguide grating biosensors in microplates. This
system consists of a temperature-control unit (26°C), an
optical detection unit, and an on-board liquid handling
unit with robotics. The detection unit is centered on in-
tegrated fiber optics, and enables kinetic measures of
cellular responses with a time interval of ~15 sec.
For DMR assays, once reached high confluency (~95%)
the cells were washed twice with assay buffer (1× Hank’s
balanced salt solution with 20 mM HEPES, pH7.1) and
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transferred to the EpicW reader for 1 hr at 26°C so a steady
baseline was reached. DMR was monitored in real time
with a temporal resolution of ~15 sec throughout the as-
says. A typical DMR proceeded with a 2-min baseline,
followed by a real time kinetic response after the com-
pound additions using the onboard liquid handler. The
DMR was recorded as a shift in resonant wavelength
(picometer, pm). Different DMR assay formats were used
for profiling opioid ligands. DMR agonist assays were used
to directly record the DMR signal arising from a ligand it-
self. DMR antagonist assays were used to record the DMR
arising from an agonist at a fixed dose (usually its EC100)
after pretreatment with an inhibitor or a ligand. An EC100
value was used to ensure maximal activation of respective
receptor for follow-up potency studies in order to have
greater antagonism differentiation power than the dose at
its EC50.
For iPOT profiling, all ligands were examined at 10
μM. This was based on three obvious reasons. First, dif-
ferent ligands often display a wide range of affinities
binding to a specific receptor, and a specific ligand often
displays distinct affinities binding to different opioid
receptors (Additional file 1). Furthermore, the binding
affinity of a ligand often does not directly translate to its
potency to activate the receptor at the whole cell level
[27,28], so it is practically difficult to choose ligand-
specific concentrations for our systematic profiling.
Second, the main purpose of the present study is to
determine both binding and functional selectivity of
the same family of ligands against the opioid receptor
family, and almost all ligands examined displayed agonist
activity in at least one of the five cell lines profiled (see re-
sults below). Thus, it is necessary to use a high concentra-
tion to saturate the receptor sites and to maximize the
functional activation of the receptors induced by most, if
not all, of the ligands examined. Third, 10 μM is the most
commonly used concentration for high throughput scree-
ning and profiling.
To manifest the specificity, relative potency and effi-
cacy, and modes of action of the drugs, a variety of
probe molecules were used to achieve a wide range of
chemical environments for each cell line through alter-
ation of cellular signaling protein(s) in the signaling
pathways of opioid receptors. Here, the cells were
pretreated offline with several probe molecules by incu-
bating the cells with a probe molecule at the indicated
dose for the indicated period of time (Table 1). After the
pretreatment with the probe molecules the cells were
then stimulated with an opioid ligand, whose responses
were recorded in real time and used for similarity and
correlation analysis. Specifically, cells were pretreated
with either 0.1% DMSO (the positive control), 10 μM
opioid ligand in the library, 100 ng/ml PTx, 400 ng/ml
CTX, 10 μM forskolin, 10 μM U0126, 10 μM SB202190,
10 μM SP600125, or 10 μM LY294002 for the times in-
dicated. Since the primary purpose of the iPOT profiling
of opioid ligands was to identify interesting ligands for
quantitative pharmacology assessment, all kinase inhibi-
tors at 10 μM were used to manifest the sensitivity of
the label-free profiles of opioid ligands to the pathway
modulation. PTX binds to Gαi, resulting in inhibition of
Gαi by ADP ribosylation of a Cys residue and uncoupling
of the G protein from the receptor [29]. CTX binds to
Gαs, resulting in activation of Gαs by ADP ribosylation of
an Arg residue and cAMP production [30]. Forskolin is
an activator of adenylyl cyclase and is widely used for
cell-based screening due to its ability to increase Gαi-
mediated signaling but desensitize Gαs-mediated signal-
ing [31]. U0126, SB202190, SP600125, and LY294002 are
known kinase pathway inhibitors for MEK1/2, p38
Table 1 Assay protocols and DMR signals used for similarity analysis
Cell Probe, pretreatment duration DMR readout Labels used in clustering Figures
HEK293 0.1% DMSO in buffer, 1 hr Ligand, 10 μM HEK-3, 9, 30 Additional file 1: Figure S1, S2
Opioid* 0.1% DMSO in buffer, 1hr Ligand, 10 μM Buffer-3, 9, 30 Figures 1 5 6 7
HEK-MOR 10 μM ligand, 1 hr DAMGO, 10 μM MOR-3, 9, 30 Additional file 1: Figures S2 & S3
HEK-DOR 10 μM ligand, 1 hr DPDPE, 10 μM DOR-3, 9, 30 Figure 5
HEK-KOR 10 μM ligand, 1 hr BRL-57532, 10 μM KOR-3, 9, 30 Figure 6
SH-SY5Y 10 μM ligand, 1 hr DAMGO, 10 μM 5Y-3, 9, 30 Figure 7
Opioid* 100 ng/ml PTX, 20 hr Ligand, 10 μM PTX-3, 9, 30 Figures 5 6 and 7
Opioid* 400 ng/ml CTX, 20 hr Ligand, 10 μM CTX-3, 9, 30 Figures 5 6 and 7
Opioid* 10 μM forskolin, 1 hr Ligand, 10 μM FSK-3, 9, 30 Figures 5 6 and 7
Opioid* 10 μM U0126, 1 hr Ligand, 10 μM U0126-3, 9, 30 Figures 5 6 and 7
Opioid* 10 μM SB202190, 1 hr Ligand, 10 μM SB-3, 9, 30 Figures 5 6 and 7
Opioid* 10 μM SP600125, 1 hr Ligand, 10 μM SP-3, 9, 30 Figures 5 6 and 7
Opioid* 10 μM LY294002, 1 hr Ligand, 10 μM LY-3, 9, 30 Figures 5 6 and 7
* Opioid receptor expressing cell lines wherein the same assay protocol was applied.
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MAPK, JNK, and PI3K, respectively [32,33]. It has been
suggested that opioid ligands often exhibit functional se-
lectivity on these pathways [5,6,34]. It is worthy of not-
ing that the results obtained using this approach may
not directly translate into a pathway-specific biased
agonism, given that many, if not all kinase inhibitors,
display polypharmacology (that is, the ability to bind to
more than one targets).
We screened a library of 64 opioid ligands. Literature
mining revealed that fifty-five of the opioid ligands in
the library had previously been shown to possess binding
affinity for at least one member of the classic opioid re-
ceptor family (Additional file 1: Tables S1–S3), and thus
chosen for analysis in this study.
Quantitative real-time PCR
Total RNA was extracted from SH-SY5Y or HEK293
cells using an RNeasy mini kit (Qiagen, Cat#74104). To
eliminate genomic DNA contamination, on-column
DNase digestion was performed using RNase-free DNase
set from Qiagen (Valencia, CA). The concentration and
quality of total RNA were determined using a Nanodrop
8000 from Thermo Scientific. Customized PCR-array
plates for 352 GPCR genes and reagents were ordered
from SABiosciences (Frederick, MD). About 1 μg total
RNA was used for each 96-well PCR-array. The PCR-
array was performed on an ABI 7300 Real-Time PCR
System following the manufacturer’s instructions.
Data visualization and clustering
For each opioid ligand in a cell line, ten DMR assays
were performed that measured receptor specificity, G-
protein coupling, and downstream kinase pathway se-
lectivity. DMR assay offers a texture rich readout for
ligand-receptor interactions at the whole cell level
[11-13]. Originating from distinct functional selectivity
and polypharmacology, the DMR signals of different li-
gands could be diverse in a specific cell [35]. To classify
ligands, we adopt similarity analysis, a technology to
cluster molecules through determination of the similar-
ity and distances among a large set of different biological
data [36-38]. For effective similarity analysis the real re-
sponses at three distinct time points (3 min, 9 min, and
30 min post-stimulation) were extracted from each kin-
etic DMR signal and used to rewrite the DMR pharma-
cology of each ligand. Combining DMR parameters from
multiple assays and/or cells formed a numerical descrip-
tor containing multi-dimensional coordinates for each
ligand, which was then subject to similarity analysis. At
least duplicate data for each assay were collected to
generate an averaged response. For visualization, the
real-time responses were color coded to illustrate rela-
tive differences in DMR signal strength. The red color
refers to a positive value, the black a value near zero,
and the green color represents a negative value. Differ-
ences in color intensity illustrate differences in signal
strength. In the ligand matrix, each column represents
one DMR response at a particular time under a specific
assay condition, and each row represents one ligand.
Every row and column carries equal weight. The Ward
hierarchical clustering algorithm and Euclidean distance
metrics [15,16] were used for generating heat maps and
clustering the DMR profiles. To assist with direct
visualization of DMR characteristics of each ligand in an
assay, we did not carry out similarity analysis among dis-
tinct columns, except for the analysis based on real time
responses (Figure 1). Each assay was arranged in three
consecutive columns to form a column group for clear
understanding of the key characteristics of a DMR.
Statistical analysis
For profiling, two independent measurements, each
done in duplicate, were performed. All replicates passed
the 2 sigma coefficient of variation test in order to be in-
cluded in the analysis. Drugs whose DMR responses
failed the statistical test were re-screened. At least two
replicates were included for the final analysis. For dose
responses, at least two independent measurements, each
done at least in duplicate, were performed to calculate
the mean responses and the standard deviations (s.d.).
Results
Expression of endogenous opioid receptors
We performed quantitative real time PCR to determine
the expression of endogenous opioid receptors in the
parental HEK293 cell line as well as SH-SY5Y cells. Re-
sults showed that HEK293 expresses low levels of
mRNAs for ORL1 (cycle threshold, Ct, 29.3), but little or
no mRNAs for MOR (Ct, undetected), DOR (Ct, 35.3),
and KOR (Ct, 33.1). As controls, the Ct values for
hypoxanthine phosphoribosyltransferase 1 (HPRT1) and
glyceraldehyde-3-phosphate dehydrogenase (GADPH) in
HEK293 were found to be 19.6 and 16.1, respectively.
Our quantitative real time PCR results also showed that
SH-SY5Y expresses mRNAs for MOR (Ct, 23.2) and
ORL1 (Ct, 25.8), low levels of mRNAs for DOR (Ct, 30.9),
and no detectable mRNAs for KOR (Ct, undetected). The
Ct values for controls were 21.3 for HPRT1, and 15.8 for
GADPH. This is consistent with previous studies show-
ing that SH-SY5Y expresses both MOR and DOR pro-
teins at a ratio of approximately 4.5:1 [20].
Label-free integrative pharmacology profiling and data
visualization
We adopted the newly developed iPOT approach to de-
termine the binding and functional selectivity of a family
of ligands against the opioid receptor family. This study
begun with the preparation of a library consisting of
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fifty-five opioid ligands, followed by whole cell DMR
profiling under different conditions and similarity ana-
lysis of respective DMR signals (Table 1). Ligands with
interesting label-free profiles were then identified and
selected for quantitative pharmacology assessment.
Interrogating SH-SY5Y cells with the library of opioid
ligands identified three types of DMR signals (Figure 1a).
Out of the fifty-five ligands tested, twenty ligands includ-
ing naloxone-HCl were silent in this cell line, leading to
a net-zero DMR. Conversely, thirty-one ligands includ-
ing DAMGO produced a positive DMR signal that con-
sists of an initial positive DMR (P-DMR) event followed
by a negative DMR (N-DMR) event. The N-DMR event
eventually decayed back to a steady level that is still
above the baseline at 1 hr poststimulation. The remaining
four ligands, DIPPA, etonitazenyl isothiocyanate, BNTX,
and ICI 199441, produced a biphasic DMR response whose













































































































Figure 1 Extracting DMR parameters for effective similarity analysis. (a) Representative DMR signals of opioid ligands in native SH-SY5Y
cells. The data represents the mean ± s.d. of 2 independent measurements, each in duplicate (n = 4). Responses at three time points (3 min,
9 min, and 30 min post-stimulation) were extracted to represent each DMR signal. The solid arrow indicates the time when ligands were added
(t =0). (b) A colored heat map of opioid ligand-induced DMR in native SH-SY5Y cells based on the responses at the three time points. (c) A
colored heat map based on the real time DMR signals of all opioid ligands that gave rise to a detectable DMR. The real time responses showed
was reduced to every minute. Three time domains were evident.
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We adopt similarity analysis to classify ligands based
on DMR responses. Given that a DMR is a kinetic re-
sponse and consists of over 200 dimensions due to its
high temporal resolution, it is practically impossible to
include all time points of a DMR signal for similarity
analysis of all ligands under all conditions. Thus, we first
reduced the DMR dimensions to three distinct time
points (3, 9, and 30 min post-stimulation) for similarity
analysis (Figure 1b). This dimensional reduction is based
on the clustering of time domains of the DMR responses
from all opioid ligands in each of the five cell lines ex-
amined. For SH-SY5Y cells, similarity analysis using the
unsupervised Ward hierarchical clustering algorithm
and Euclidean distance metrics [15,16] showed that all
DMR signals with an amplitude greater than 30 pm gen-
erally propagate with three distinct time periods: imme-
diate (1–8 min), early (9–15 min), and late responses
(15–50 min post-stimulation) (Figure 1c). Clustering
based on the entire kinetic response or the reduced
three time-points led to similar clusters of ligands in
SH-SY5Y cells (comparing Figure 1c with b), although
clustering based on the entire kinetic response expect-
edly gave rise to better resolution than by using the
reduced time-points. Therefore, we chose to limit our
analysis to the three time point parameters (3, 9, and
30 min) for each DMR response.
Selectivity of opioid agonists at the opioid receptor
family
We first determined the selective agonist activity of opioid
ligands in five distinct cell lines using DMR agonist assays,
based on their ability to trigger DMR signals in respective
cell lines. For the four opioid receptor-expressing cell
lines, we included both positive and negative controls to
define the range of responses for classification of ligand
agonism. For the negative controls (that is, the assay buf-
fer containing equal amount of DMSO), the DMR re-
sponses at 9 min poststimulation were found to be 3±12
pm, -4±14 pm, 5±11 pm and 3±5 pm (n = 16) for HEK-
MOR, HEK-DOR, HEK-KOR and SH-SH5Y cells, respect-
ively. For the positive controls, the DMR responses at
9 min poststimulation were found to be 240±17 pm, 321
±26 pm, 213±21 pm, and 87±9 pm (n = 32) for 10 μM
DAMGO in HEK-MOR, 10 μM DPDPE in HEK-DOR, 10
μM BRL52537 in HEK-KOR, and 10 μM DAMGO in SH-
SH5Y cells, respectively. For a given cell line, a ligand
whose DMR amplitude was within the mean±2σ of its
positive control was considered to be a full agonist, while
a ligand whose DMR amplitude was smaller the mean-2σ
of its positive control and greater than 50 pm was consid-
ered to be a partial agonist, and a ligand whose DMR
amplitude was smaller than 50 pm was considered to be
inactive. A ligand that led to a detectable DMR in
HEK293 was viewed to have off-target effect(s).
Table 2 summarizes the agonist activity of all opioid li-
gands in the five different cell lines. Out of the fifty-five
ligands tested, six off-target ligands including BNTX, β-
funaltrexamine, etonitazenyl isothiocyanate, ICI 199441,
dynorphin A 2–13 and nocicepin 1–13 gave rise to a no-
ticeable DMR in the parental HEK293 cells (Additional
file 1: Figure S1). Among the six ligands only BNTX led
to an N-DMR in all five cell lines, while the others pro-
duced a P-DMR signal in the four opioid receptor-
expressing cell lines.
Out of the fifty-five ligands tested, four ligands includ-
ing naloxone was inactive in all cell lines, while the other
forty-nine ligands gave rise to agonist activity in at least
one of the four opioid receptor-expressing cell lines.
Several ligands that are believed to be opioid antagonists
also produced noticeable DMR in at least one of the
engineered cell lines, but not in SH-SH5Y cells. Specific-
ally, nalbuphine and β-funaltrexamine acted as partial ago-
nists at MOR, DOR, and KOR sites, while levallorphan,
SKF10047 and N-benzylnaltrindole specific to both DOR
and KOR sites, and naloxonazine and naltrexone specific
to the KOR.
The pattern of agonist activity in SH-SY5Y cells
(Additional file 1: Figure S2) cannot be explained by the
solo activation of endogenous MOR, and/or by the
differential expression levels of the MOR between SH-
SY5Y and HEK-MOR cells. This is expected given that
SH-SY5Y expresses both MOR and DOR. This conclu-
sion was supported by correlation analysis between the
two cell lines (Figure 2). This analysis excluded the six
off-target ligands, and all other responses were normal-
ized to the DAMGO response in respective cell line. Re-
sults showed that SNC 121, SNC80 and deltrophin II
had no or little activity in the HEK-MOR, but active in
SH-SY5Y cells. In contrast, tramadol was active in HEK-
MOR, but inactive in SH-SY5Y cells. Similarly, a group
of ligands including U-50488H, U62066, DIPPA and
(−)U-50488H were active in the three transfected cell
lines, but not in SH-SY5Y cells. Furthermore, DPDPE and
GR89696 behaved as partial agonists in HEK-MOR cells,
but full agonists in SH-SY5Y cells.
Selectivity of opioid ligands to block the DMR response
produced by the activation of opioid receptors
We used a two-step DMR assay (i.e., an antagonist assay)
to determine the ability of opioid ligands to block or
desensitize the DMR responses resulting from the activa-
tion of opioid receptors. The antagonist or desensitization
assay was performed in two sequential steps, each lasting
about one hour. Cells were pretreated with a ligand from
the opioid library, followed by treatment with a fixed dose
of a known opioid agonist. A ligand that does not trigger a
DMR but blocks the DMR of the known agonist is termed
an antagonist. Conversely, a ligand that leads to noticeable
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Table 2 Classification of opioid ligands based on their DMR agonist activity in the five distinct cell lines
Name HEK MOR DOR KOR SH-SY5Y Literature classification
β-Funaltrexamine off-target Partial agonist Partial agonist Partial agonist Mu antagonist
BNTX off-target off-target off-target off-target off-target Delta antagonist
Dynorphin A (2–13) off-target Partial agonist Partial agonist Kappa agonist
Etonitazenyl off-target Partial agonist Partial agonist Mu agonist
ICI 199,441 off-target Full agonist Partial agonist Full agonist Kappa agonist
Nociceptin (1–13) off-target Partial agonist Partial agonist ORL1 agonist
α-Neoendorphin Partial agonist Full agonist Full agonist Full agonist Kappa agonist
BRL-52537 Partial agonist Full agonist Kappa agonist
BUBUC Partial agonist Full agonist Partial agonist Partial agonist Delta agonist
DADLE Partial agonist Full agonist Partial agonist Full agonist Delta agonist
DALDA Partial agonist Full agonist Mu agonist
DAMGO Full agonist Partial agonist Partial agonist Full agonist Mu agonist
DAMME Full agonist Full agonist Partial agonist Full agonist Mu/Delta agonist
Deltorphin II Partial agonist Full agonist Delta agonist
DIPPA Partial agonist Partial agonist Full agonist Kappa antagonist
DPDPE Partial agonist Full agonist Partial agonist Full agonist Delta agonist
DSLET Full agonist Full agonist Partial agonist Full agonist Delta agonist
DTLET Full agonist Full agonist Partial agonist Full agonist Delta agonist
Dynorphin A (1–13) Full agonist Full agonist Full agonist Partial agonist Kappa agonist
Dynorphin A (1–8) Full agonist Full agonist Full agonist Full agonist Kappa agonist
Dynorphin B Partial agonist Full agonist Full agonist Full agonist Kappa agonist
Endomorphin-1 Partial agonist Partial agonist Partial agonist Mu agonist
Endomorphin-2 Partial agonist Partial agonist Partial agonist Full agonist Mu agonist
(Leu5)-Enkephalin Full agonist Full agonist Partial agonist Full agonist Mu/Delta agonist
(Met5)-Enkephalin Full agonist Full agonist Partial agonist Full agonist Mu/Delta agonist
GR 89696 Partial agonist Partial agonist Full agonist Full agonist Kappa agonist
ICI 204,448 Partial agonist Partial agonist Full agonist Full agonist Kappa agonist
Levallorphan Partial agonist Partial agonist Partial Mu/delta agonist
Morphiceptin Partial agonist Partial agonist Mu agonist
Nalbuphine Partial agonist Partial agonist Partial agonist Partial Mu/kappa agonist
Naloxonazine Partial agonist Mu antagonist
Naloxone HCl Opioid antagonist
Naloxone methiodide Opioid antagonist
Naltrexone Partial agonist Opioid antagonist
Naltriben Delta antagonist
Naltrindole Delta antagonist
N-Benzylnaltrindole Partial agonist Partial agonist Delta antagonist
N-MPPP Partial agonist Partial agonist Full agonist Kappa agonist
NNC 63-0532 Partial agonist Partial agonist Partial agonist Full agonist ORL1 agonist
Nociceptin Partial agonist ORL1 agonist
Nor-Binaltorphimine Kappa antagonist
(−)-Norcodeine Partial agonist Partial agonist Partial agonist Opioid antagonist
Salvinorin A Partial agonist Full agonist Kappa agonist
SKF10047 Partial agonist Partial agonist Opioid agonist/antagonist
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DMR response but desensitizes the cells responding to the
succeeding agonist is termed an agonist.
We first determined the DMR potency of a known
agonist for each cell line: DAMGO for HEK-MOR,
DPDPE for HEK-DOR, BRL-52537 for HEK-KOR, and
DAMGO for SH-SY5Y cells, based on their respective
maximal amplitudes. We have previously shown that
DAMGO produces a mono-phasic dose response in
HEK-MOR cells with an EC50 of 0.93±0.12 nM [16]. In
HEK-DOR cells, DPDPE produced biphasic dose re-
sponse with two distinct EC50’s of 0.15±0.03 nM, and 2.8
±0.09 nM (2 independent measurements, n =4) (Figure 3a
and b). In HEK-KOR cells, BRL-52537 also produced a bi-
phasic dose response with two distinct EC50’s of 35.6±3.1
pM, and 26.0±1.9 nM (2 independent measurements, n
=4) (Figure 3c and d). Conversely, in SH-SY5Y cells
DAMGO produced a monophasic dose response with an
EC50 of 4.5±0.3 nM (2 independent measurements, n =4)
(Figure 3e and f).
We next performed cluster analysis of the known
agonist DMR responses after pretreatment with the li-
brary ligands using unsupervised Ward hierarchical clus-
tering algorithm and Euclidean distance metrics. To
achieve high resolution to differentiate the relative po-
tency of opioid ligands to block or desensitize the agon-
ist DMR response at each receptor site we employed a
high dose for each agonist tested (10 μM DAMGO for
HEK-MOR cells, 10 μM DPDPE for HEK-DOR cells, 10
μM BRL-52537 for HEK-KOR cells, and 10 μM DAMGO
for SH-SY5Y cells). The DMR of each known agonist in its
respective cell line was shown to be specific to the activa-
tion of its respective receptor. Results showed that the
cluster analysis separated these ligands into different clus-
ters (Additional file 1: Figure S3), and most of the ligands
in each subcluster exhibited DMR characteristics in gen-
eral agreement with their previously described pharmacol-
ogy and classifications (Table 2 and Additional file 1:
Tables S1–S3).
We further examined the DMR responses of DAMGO
in SH-SY5Y cells with and without pretreatment with
the library ligands, based on reported affinities of opioid
ligands (Additional file 1: Tables S1 to S3) [39]. Results
show that the ligands blocking the DAMGO-elicited
DMR in HEK-MOR also blocked the DAMGO DMR in
SH-SY5Y cells, suggesting that the DAMGO response in
SH-SY5Y is mostly originated from the activation of the
MOR. However, the extent of the DAMGO-induced
DMR observed after pretreatment with the library of
opioid ligands in SH-SY5Y cells cannot be explained by
the known affinities of these ligands binding to MOR or
the DOR sites (Figure 4a and b). To best illustrate this,
we first assumed that the DAMGO DMR in SH-SY5Y
cells is originated from the activation of MOR or DOR
alone, and then compared the actual DAMGO response
with the calculated one for each ligand based on its
Table 2 Classification of opioid ligands based on their DMR agonist activity in the five distinct cell lines (Continued)
SNC 121 Partial agonist Partial agonist Partial agonist Delta agonist
SNC 80 Partial agonist Partial agonist Partial agonist Partial agonist Delta agonist
Syndyphalin SD-25 Full agonist Partial agonist Partial agonist Partial agonist Mu agonist
TAPP Partial agonist Partial agonist Partial agonist Full agonist Mu agonist
Tramadol Partial agonist Weak Mu agonist
(−)-U-50488 Partial agonist Partial agonist Full agonist Kappa partial agonist
(+)-U-50488 Full agonist Kappa partial agonist
U-50,488H Partial agonist Partial agonist Full agonist Kappa agonist
U-54494A Partial agonist Partial agonist Partial agonist Kappa agonist
U-62066 Partial agonist Full agonist Kappa agonist
U-69593 Partial agonist Partial agonist Full agonist Kappa agonist




































Figure 2 The correlation analysis of the DMR of forty-nine
opiate ligands in HEK-MOR cells versus SH-SY5Y cells after
normalized to the DAMGO DMR. All ligands were assayed at
10 μM.
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reported affinity for the MOR (Figure 4a) or DOR
(Figure 4b), respectively. This analysis showed that three
potent MOR antagonists, β-funaltrexamine, levallorphan
and nor-binaltorphimine, appeared to be less potent to
block the DAMGO-induced DMR in SH-SY5Y cells than
that would be expected at MOR binding sites; conver-
sely, three agonists including SKF10047, ICI 199,441 and
DIPPA desensitized SH-SY5Y cells with greater potency
than their reported affinities at the MOR, and the re-
maining ligands gave rise to expected results (Figure 4a).
This suggests that the DAMGO response has addi-
tional signaling component beside the MOR. Further,
the DOR-selective agonists including deltorphin II,
SNC121, BUBUC, SNC80 and DPDPE desensitized SH-
SY5Y cells with lower potency than that would be
expected at DOR binding sites, but the rest ligands be-
haved as expected at DOR binding sites (Figure 4b),
suggesting that the DAMGO response in SH-SY5Y cells
has additional signaling component beside the DOR. As
comparison, the DAMGO induced DMR in HEK-MOR
cells after pretreatment with library ligands was corre-
lated well with their known binding affinities, with an
exception of a group of antagonists including nor-
binaltorphimine, N-benzylnatrindole, naloxone methiodide,
naltrindole, and naltriben (Figure 4c). Similarly, the
DPDPE-induced DMR in HEK-DOR cells after the ligand
pretreatment was mostly correlated well with their known
binding affinities, except for a group of opioid antagonists
including naloxone HCl (Figure 4d). The partial blockage
of the DAMGO response in HEK-MOR, or of the DPDPE
response in HEK-DOR by these antagonists is partially due
to the use of high dose agonists used (10 μM for both
agonists). Other factors such as receptor dimerization or
differing cellular contexts may also contribute to these dif-
ferences. Nonetheless, these results suggest that ligand
pharmacology at the whole cell level is different from the
in vitro binding profiles.
Functional selectivity of opioid ligands at the opioid
receptors
We hypothesized that functional selectivity of a ligand
at the whole cell level is reflected by the sensitivity of its
DMR response to pretreatment of cells with various
probe molecules [15,16]. We excluded BNTX, β-
funaltrexamine, etonitazenyl isothiocyanate, ICI 199441,
dynorphin A2-13 and nocicepin 1–13 from biased agon-
ism analysis because of their off-target activity. To ef-
fectively visualize the effect of the probe pretreatments,
we used the net change of the DMR response of a ligand
(i.e., Its DMR in a probe molecule pretreated cells
minus its DMR in DMSO treated cells) for similarity
analysis. This was done for all assay conditions except
for PTX pretreatment wherein the raw DMR were used,
since these DMR are generally small with amplitudes
similar to the net change in other probe-treated cells –
an important consideration for accurate clustering. The















































































































































Figure 3 Dose-dependent responses of agonists in distinct cell lines. (a, b) Dose responses of DPDPE in HEK-DOR; (c, d) Dose responses of
BRL-52537 in HEK-KOR; and (e, f) Dose responses of DAMGO in SH-SY5Y cells. (a, c, e) Real time DMR, each curve represents the mean ± s.d. of 2
independent measurements, each in duplicate (n = 4). (b, d, f) The maximal amplitudes as a function of agonist doses (n = 4).
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DMR in the DMSO treated cells were also included as
references. A positive net change indicates that the
probe pretreatment potentiates a ligand-induced DMR
response, while a negative net change indicates a de-
crease in a ligand-induced DMR response by the probe
pretreatment. The averaged responses of at least 2 ex-
periments were used. Statistical analysis showed that for
a total of 2× 3960 DMR data points obtained (3 cell
lines × 8 assay conditions × 55 ligands × 3 time points),
97.1% gave rise to an absolute difference between repli-
cates for a ligand under one condition that was smaller
than 10 pm, and the remaining 2.9% (115 parameters,
all of which occurred in either HEK-DOR or HEK-KOR
cells) was between 10 and 20 pm. Thus, a net change in-
duced by a probe pretreatment greater than 30 pm was
considered to be significant for both HEK-DOR and
HEK-KOR cells, while a net change greater than 20 pm
was to be significant for SH-SY5Y cells.
Profiling HEK-DOR cells after pretreatment with seven
probe molecules produced a heat map which grouped
the ligands into two large superclusters (Figure 5). Not-
ably, all ligands gave rise to a P-DMR response under at
least one assay condition. The first supercluster consists
of antagonists and ligands that were inactive in the
untreated HEK-DOR cells, except for endomorphin-1
which acted as a partial agonist in the control HEK-
DOR cells (i.e., the cells pretreated with the vehicle
only). All ligands in this supercluster exhibited a small
P-DMR in the forskolin-pretreated cells, suggesting that
these ligands gave rise to weak partial agonist activity
when the basal cAMP level is high. The second super-
cluster can be further subdivided into three subclusters,
one for ligands such as DPDPE who appear to act as full
agonists, and two others comprised of ligands that
appear to act as partial agonists. For the full agonist
subcluster, these ligands still triggered a noticeable DMR
response in PTX-pretreated cells; CTX pretreatment gen-
erally increased their DMR; forskolin only increased their
early DMR response but suppressed their late DMR re-
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Nalbuphine    
DAMGO
Figure 4 The inhibition pattern by opioid ligands. (a) The percentage of DAMGO responses in SH-SY5Y cells as a function of the binding
affinity of opioid ligands to the MOR. (b) The percentage of DAMGO responses in SH-SY5Y cells as a function of the binding affinity of opioid
ligands to the DOR. (c) The percentage of DAMGO responses in HEK-MOR cells as a function of the binding affinity of opioid ligands to the MOR.
(d) The percentage of DPDPE responses in HEK-DOR cells as a function of the binding affinity of opioid ligands to the DOR. The percentage of
agonist responses after pretreatment with ligands in the library were calculated based on the normalization of the agonist response in the
presence of a ligand to the positive control (i.e., the agonist response after pretreatment with the vehicle buffer only). The data points in pink
were calculated based on the known binding affinity of each ligand against the specific receptor using% agonist response = 1/[1 + 10^log (X –
Ki)], wherein X is the concentration of each ligand, and Ki the binding affinity obtained in literature. Included in this analysis are ligands whose
binding affinities at specific receptor sites are known.
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and LY294002 generally increased their DMR; but
SB202190 suppressed their DMR. The second subcluster
was comprised of DIPPA, dynorphin A 1–13, NNC63-
0532, N-benzylnaltrindole, and U-5449A, all of which
were insensitive to U0126, SP600125 and LY294002 pre-
treatment. However, only DIPPA and dynorphin A 1–13
produced a noticeable DMR response in PTX treated cells
and led to an increased DMR in the CTX or forskolin
treated cells. Forskolin pretreatment selectively suppressed
the late DMR of dynorphin A 1–13, and SB202190 only
suppressed the DMR of DIPPA, dynorphin A 1–13,
NNC63-0532, N-benzylnaltrindole. The third subcluster
consists of fifteen ligands including endomorphin-2, none
of which produced any DMR response in PTX- treated
cells. All ligands in this subcluster were insensitive to the
pretreatment with CTX, U0126 or SB202190, but were
increased by forskolin pretreatment. Together, these re-
sults suggest that the opioid ligands are divergent in their
biased agonism at the DOR.
The DMR profiles obtained in HEK-KOR cells under
the eight assay conditions produced a heat map that also
separated the ligands into two superclusters (Figure 6).
The first cluster consists of the DMSO negative control
and nor-binaltorphimine. The absence of any DMR under
all conditions suggests that nor-binaltorphimine behaved
as a true neutral antagonist at the KOR. The second
supercluster can be further subdivided into multiple sub-
clusters, each of which produced a P-DMR signal under at
least one assay condition. Agonists that produced a de-
tectable P-DMR in the PTX pretreated cells include
DIPPA, dynorphin B, α-neoendorphin, dynorphin A 1–8,



















































































































































Figure 5 A colored heat map based on the functional selectivity of opioid ligands at the DOR. The DMR signals of ligands in HEK-DOR
cells with and without (i.e., buffer) pretreatment with probe molecules including PTX, CTX, U0126, SB202190, SP600125 and LY294002 were used
to generate the heat map. All of the ligands in the library were assayed at 10 μM. The negative control (DMSO) was also included. To effectively
visualize the impact of probe molecules, the net change for each ligand after pretreatment was obtained via subtraction, except for both the
positive control (i.e., DMR in cells pretreated with the buffer vehicle only) and the ligand DMR in PTX-pretreated cells for which the raw data
were used.
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U-69595, U-62066, BRL-52537, and GR89696. Unlike the
situation in HEK-MOR and HEK-DOR cells, the DMR re-
sponses of almost all agonists were found to be insensitive
to both CTX- and forkolin-pretreatment in HEK-KOR
cells. A similar pattern was observed for both SP600125-
and LY294002-treatment. However, pretreatment of HEK-
KOR cells with SB202190 suppressed the ligand-library
DMR response induced by virtually all agonists, with
U-50488H exhibiting the most significant suppression.
Further, U0126 selectively suppressed the DMR of (−)-U-
50488 and U-50488H. Together, these results suggest that
p38 MAPK pathway may play a more significant role in
the KOR signaling than any of the other kinase pathways.
We next profiled the opioid library ligands using SH-
SY5Y cells under the eight different assay conditions. Re-
sults showed that SH-SY5Y cells led to different patterns
for the library ligands (Figure 7). Ligands in the agonist
supercluster typically behaved as would be expected.
However, some ligands, most notably DIPPA, produced
unique DMR responses – DIPPA triggered a biphasic DMR
response which eventually decayed below the baseline in
the native SH-SY5Y cells, while PTX pretreatment
suppressed both the early and late DMR response; both
CTX and forskolin potentiated the DMR response; U0126
converted the DMR response to a single phase N-DMR;
and SB202190 delayed the time to reach its peak. This
unique pattern suggests that DIPPA activates both Gαi-
dependent and independent pathways. Except for DAMGO
and TAPP, ligands in the agonist supercluster led to little or
no DMR in the PTX-treated cells. Both CTX and forskolin
suppressed the DMR of dynorphin A 1–8, DPDPE or
DALDA. Forskolin also suppressed the DMR of Leu5-
enkephalin, DSLET and DAMME. In general, the kinase in-
hibitors mostly suppressed the same group of agonists
which included dynorphin A 1–8, DPDPE, DALDA,



















































































































































Figure 6 A colored heat map based on the functional selectivity of opioid ligands at the KOR. All of the ligands in the library were
assayed at 10 μM. The negative control (DMSO) was also included. To effectively visualize the impact of probe molecules, the net change for
each ligand after pretreatment was obtained via subtraction, except for both the positive control (i.e., DMR in cells pretreated with the buffer
vehicle only) and the ligand DMR in PTX-pretreated cells for which the raw data were used.
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pharmacology in SH-SY5Y cells is distinct from those in
both HEK-MOR and HEK-DOR.
Potency and efficacy of opioid ligands at distinct opioid
receptors
Based on the iPOT profiles, we further examined the
dose responses of selected ligands at distinct opioid re-
ceptors. For HEK-DOR cells, besides DPDPE five add-
itional ligands were profiled using both DMR 1-step
agonist and 2-step antagonist assays. The agonist DMR
assays showed that four of these ligands including DPDPE,
DAMGO, ICI 199441 and naltrindole, gave rise to dose-
dependent responses in HEK-DOR cells (Figure 8a) while
naltriben and naloxone HCl were silent in HEK-DOR
cells. DPDPE resulted in a biphasic dose response,
resulting to two saturable amplitudes, 279±11 pm and 415
±17 pm (n =16), respectively (Figure 3a and b). However,
all other agonists led to a monophasic dose response,
yielding an EC50 of 281.1±21.3 nM ( n = 4), 104.8±4.9 nM
(n =4) and 6.1±0.9 nM (n =4) for ICI 199441, DAMGO
and naltrindole, respectively (Figure 8a). The correspon-
ding maximal amplitudes were found to be 300±23 pm
(n =16), 235±13 pm (n =16) and 82±9 pm (n =16).
The DMR antagonist assay showed that distinct li-
gands differentially blocked the succeeding DPDPE-
induced DMR response in HEK-DOR cells (Figure 8b
and c). The dose-dependent desensitization by DPDPE is
best fitted with single phase sigmoidal non-linear regres-
sion, leading to an IC50 of 1.25±0.10 nM (n = 4). Similar
monophasic inhibitory dose-responses were obtained for
naltrindole (IC50, 8.87±0.39 nM; n = 4), ICI 199441
(IC50, 753±67 nM; n = 4), and naltriben (IC50, 5.30±0.36
nM; n = 4). However, a biphasic dose-dependent inhib-
ition of the DPDPE-induced DMR was observed for the
partial agonist DAMGO (IC50: 368±51 nM and 7.58
±1.32 μM; n =4), and the antagonist naloxone HCl (IC50:
135.1±14.9 nM and 6.41±0.75 μM; n =4).
We next characterized the KOR using four opioid li-
gands, including BRL-52537. The DMR agonist assay























































































































































Figure 7 A colored heat map based on the functional selectivity of opioid ligands at the endogenous receptor in SH-SY5Y cells. All of
the ligands in the library were assayed at 10 μM. The negative control (DMSO) was also included. To effectively visualize the impact of probe
molecules, the net change for each ligand after pretreatment was obtained via subtraction, except for both the positive control (i.e., DMR in cells
pretreated with the buffer vehicle only) and the ligand DMR in PTX-pretreated cells for which the raw data were used.
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DMR signals (Figure 9a), similar to BRL-52537 (Figure 3b).
Like BRL-52537, DIPPA and DAMGO all yielded biphasic
dose responses. This analysis revealed EC50 values of 13.4
±1.5 nM and 239.6±11.2 nM (n = 4) for DIPPA, and 93.8
±7.4 nM and 4.5±1.1 μM (n =4) for DAMGO. The two
saturable amplitudes were 120±6 pm and 207±13 pm
(n = 4) for BRL-52537, 138±8 pm and 205±9 pm (n = 4)
for DIPPA, and 139±6 pm and 200±8 pm (n = 4) for
DAMGO. In contrast, the partial agonist naloxone HCl
yielded a monophasic dose response with an EC50 of 1.4
±0.2 nM, with a maximal response of 69±5 pm (n = 4).
Further, the two-step DMR antagonist assay showed that
distinct ligands differentially inhibited the HEK-KOR cells
responding to repeated stimulation with 64 nM BRL-
52537 (Figure 9b). DIPPA, DAMGO and BRL-52537 each
inhibited the BRL-52537 response with single phase sig-
moidal non-linear regression producing IC50 values of
454.9±32.3 nM (n = 4), 2.21±0.51 μM, and 4.1±0.23 nM,
respectively. In contrast, the dose-dependent inhibition by
the antagonist naloxone HCl was best fitted with a bi-
phasic sigmoidal non-linear regression, which exhibited
biphasic IC50’s of 67.2±5.6 nM and 2.05±0.0.54 μM
(n = 4).
Lastly, we characterized the DMR response elicited by
opioid receptors in SH-SY5Y cells utilizing seven known
agonists and antagonists. Results from the DMR agonist
assay showed that all ligands yielded dose-dependent P-
DMR signals, except for naloxone HCl, which did not
produce any observable DMR response in SH-SY5Y cells
(Figure 10a). Similar to DAMGO (Figure 3e), the dose-
dependent activation responses were best fitted using a sin-
gle phase sigmoidal non-linear regression, revealing EC50
values of 26.5±2.1 nM (n = 4), 1.4±0.2 nM (n = 4), 2.4±0.2
nM (n = 4), 1.2±0.1 nM (n = 4), and 2.8±0.3 nM (n = 4) for
morphine, fentanyl, endomorphin-1, endomorphin-2 and
CTOP, respectively (Figure 10a). The maximal DMR re-
sponses were found to be 102±8 pm, 94±5 pm, 105±7 pm,
102±6 pm, 102±7 pm, and 31±4 pm (n = 16 for all)
for DAMGO, morphine, fentanyl, endomorphin-1,
endomorphin-2 and CTOP, respectively. The two-step
DMR antagonist assay showed that all ligands blocked
the DMR produced by 64 nM DAMGO in a dose-
dependent fashion. Single IC50 values of 1.0±0.1 nM,
115.8±14.7 nM, 4.2±0.3 nM, 10.0±0.9 nM, 5.8±0.4
nM, 475.5±39.7 nM, and 231.4±21.5 nM were obtained
for DAMGO, morphine, fentanyl, endomorphin-1,
endomorphin-2, CTOP, and naloxone HCl, respectively
(Figure 10b). Together, these results suggest that the fam-
ily of opioid receptors exhibit complex pharmacology.
Discussion
Functional selectivity represents the underlying basis for
drug selectivity, one of the most important pharmaco-
logical properties of drug molecules which assist to de-
termine their in vivo efficacy and therapeutic index.
However, functional selectivity has not been fully inte-
grated into the mainstream drug discovery and develop-
ment processes. This is partly because of the simplistic
molecular assays conventionally used to characterize the
pharmacological properties of many drug molecules and
partly because of unknown molecular mode(s) of action
that is critical to in vivo efficacy or in vivo side effects of
drugs. This issue is exemplified by opioid ligands. Mo-
lecular assays have revealed a wide array of biased agon-
ism demonstrated by opioid ligands which appear to be
cell-systems and assay technology dependent [5,6,34].
However, multidimensional biased agonism makes it dif-
ficult to rank candidate compounds for in vivo testing
and to relate a specific biased agonism of drug molecules
to their in vivo profiles.
Many opioid ligands often display relatively poor se-
lectivity binding to different opioid receptor family
members [39,40]. This problem is exacerbated by the
fact that the binding affinity profiles of opioid ligands do

































































Figure 8 Dose responses of a panel of opioid ligands in HEK-DOR cells. (a) Dose dependent responses of opioid ligands obtained using
DMR agonist assays. The maximal amplitudes were plotted as a function of agonist doses. (b) Dose-dependent desensitization by the DOR
agonists of HEK-DOR cells to the repeated stimulation with DPDPE at 64 nM. (c) Dose-dependent inhibition by the DOR antagonists of HEK-DOR
cells to the succeeding stimulation with DPDPE at 64 nM. For (b) and (c) the maximal amplitudes of the DPDPE DMR were plotted as a function
of ligand doses, and data represents the mean ± s.d. for 2 independent measurements, each in duplicate (n = 4).
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not directly translate into their selectivity in cellular and
in vivo environments due to the expression of more than
one opioid receptor or its splice variants in native cells,
as well as the possibility that opioid receptors may
present in different oligomerizational states [41-45].
Thus, an effective means to differentiate drug candidate
molecules based on both binding and functional selectiv-
ity in native cells would be beneficial to identify and
prioritize lead compounds, and to relate in vitro results
to in vivo profiles.
Recently, we have developed a label-free iPOT ap-
proach and applied it to differentiate individual ligands
in libraries for both β2-adrenergic receptor [15] and the
MOR [16]. High resolution heat maps obtained allowed
us to sort these ligands into distinct clusters based on
their cellular binding profiles and pathway biased agon-
ism. Here, we extended this approach to survey the
entire classic opioid receptor family (mu-, kappa- and
delta-receptors). Both recombinant and native cells ex-
pressing opioid receptors were used to generate DMR
profiles of a library of opioid ligands using a battery of
DMR assay formats. The DMR profiles for all the ligands
were translated into numerical coordinates which were











































Figure 9 Dose responses of a panel of opioid ligands in HEK-
KOR cells. (a) Dose dependent responses of opioid ligands
obtained using DMR agonist assays. The maximal amplitudes were
plotted as a function of agonist doses. Data represents the mean ±
s.d. for 2 independent measurements, each in duplicate (n = 4).
(b) Dose-dependent inhibition of the DMR of 64 nM BRL-57532 by
opioid ligands. The maximal amplitudes of the BRL-57532 DMR were
plotted as a function of ligand doses. Data represents the mean ± s.
d. for 2 independent measurements, each in duplicate (n = 4).


















































Figure 10 Dose responses of a panel of opioid ligands in SH-
SY5Y cells. (a) Dose dependent responses of opioid ligands
obtained using DMR agonist assays. The maximal amplitudes were
plotted as a function of agonist doses. (b) Dose-dependent
inhibition of the DMR of 64 nM DAMGO by opioid ligands. The
maximal amplitudes of the DAMGO DMR were plotted as a function
of ligand doses. For (a) and (b) data represents the mean ± s.d. for 2
independent measurements, each in duplicate (n = 4).
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subject to similarity analysis to determine the similarity
and distance between ligand pairs. The results obtained
were visualized using a color-coded heat map with a
distance-dendrogram. Here, a variety of probe molecules
such as a kinase inhibitor (e.g., SB202190) were used to
pretreat the cells in order to manifest the sensitivity of a
ligand-induced DMR to the altered cellular background.
Such sensitivity is primarily used as a differentiating fac-
tor for ligand classification, rather than for determining
the exact cellular mechanism of functional selectivity at
a specific pathway (e.g., p38 MAPK activation). This is
because kinase inhibitors such as SB202190 are known
to inhibit multiple targets, and DMR is a whole cell re-
sponse. On the other hand, MOR, KOR and DOR all
can result in p38 MAPK activation in a cell context
dependent manner, and kinase cascades have been pro-
posed to be a basis to differentiate ligand-directed sig-
naling at opioid receptors [34]. Our data indicate that
compared to those in HEK-MOR, HEK-DOR and native
SH-SH5Y cells, the DMR of almost all agonists in the
HEK-KOR cells exhibited much higher sensitivity to the
SB202190 pretreatment, suggesting that p38 MAPK
pathway may be more important in the KOR signaling.
However, the biological implications still need further
elucidation.
This methodology led to several interesting findings.
First, the off-target activity of a subset of ligands includ-
ing BNTX, β-funaltrexamine, etonitazenyl isothiocyan-
ate, ICI 199,441, dynorphin A 2–13 and nociceptin 1–13
was visualized in both HEK293 and SH-SY5Y cells, indi-
cating that DMR assays are indeed capable of character-
izing molecules with much wider pathway coverage than
conventional pharmacological or molecular assays.
Second, opiate ligands were found to display distinct
pharmacology in MOR or DOR stably expressed cell
lines versus the native SH-SY5Y cells. Such a cellular
background-dependent pharmacology, termed pheno-
typic pharmacology, is common to many GPCR ligands
[46], and is believed to be originated from many differ-
ent factors [47-49]. The specific cellular mechanisms
causing the differential pharmacology of these ligands in
different opioid receptor expressing cells are unknown,
and further studies are warranted.
Third, almost all ligands in the library behaved as ago-
nists in at least one opioid receptor expressing cell line
with or without pretreatment with probe molecules.
Using the DMR agonist assay, we found that out fifty-
five opioid ligands testes, forty-nine displayed agonist ac-
tivity in at least one opioid receptor-expressing cell line
(Table 2). This is significant since as many as thirteen li-
gands in the library were classified as opioid receptor
antagonists (Table 2, Additional file 1: Tables S1–S3).
Furthermore, all ligands displayed agonist activity in at
least one opioid receptor expressing cell lines under one
condition. In HEK-KOR cells, nor-binaltorphimine was dis-
tinct as it did not trigger any DMR response under any
conditions, leading us to conclude that nor-binaltorphimine
was a true neutral antagonist for the KOR.
Fourth, pathway biased agonism was also visualized
for many ligands. First, Gαi-independent signaling was
evident in the DMR produced by a subset of ligands in
PTX-treated cells. Generally full agonists and strong par-
tial agonists for each receptor led to a detectable DMR
response in PTX-treated cells, indicative of activating
Gαi-independent signaling. An alternative mechanism is
that PTX treatment unnaturally shifts receptor signaling
to a different signal transduction pathway. As such the
lack of a complete blockade of signal with PTX does not
necessarily mean that under naïve conditions (when
functional Gαi is present) a ligand signals through Gαi -
independent pathways. Second, CTX and forskolin
pretreatment generally increased the DMR response in-
duced by opioid agonists in both HEK-MOR [16] and
HEK-DOR cells (Figure 5), but clearly suppressed the
DMR of a subset of opioid ligands in HEK-KOR and
SH-SY5Y cells (Figures 6 and 7, respectively). These pat-
terns suggest that the KOR in HEK-KOR cells and the
opioid receptors in SH-SY5Y may also signal via a path-
way distinct from Gαi.
Lastly, the iPOT analysis of opioid ligands further indi-
cates the complexity of opioid ligand pharmacology.
First, the difference in ligand specificity between HEK-
MOR and SH-SY5Y cells, or between HEK-DOR and
SH-SY5Y cells (Figure 4) cannot be explained solely by
the known affinity of these ligands for the MOR or for
the DOR, respectively [39]. Such a difference seems to
be reflective of the presence of different populations of
endogenous opioid receptors or the different level and
complement of second messengers and signal transduc-
tion components in SH-SY5Y cells. Second, the dose-
dependent efficacy and potency of panels of ligands to
activate opioid receptors, together with the dose-
dependent desensitization/inhibition of the activation of
opioid receptors, clearly shows that different ligands
produce very different types of dose responses. These re-
sponses may be monophasic or biphasic in a ligand- and
cell-dependent manner. The biphasic dose responses in
opioid receptor expressing cells observed for certain ag-
onists may be related to dual modes of action of the li-
gands acting at a receptor; that is, the ligands at low
doses are biased to a specific pathway, but at higher
doses the ligands activate a broader range of pathways
[50]. Alternatively, a biphasic dose response for agonists
and antagonists may be associated with the existence of
different receptor states such as functional monomers
and oligomers [51]. A ligand may have different potency
to activate or deactivate distinct receptor populations.
Nonetheless, the present study represents the first study
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using label-free cellular assays to assess the binding and
functional selectivity of opioid ligands across the entire
classic opioid receptor family.
We are still at the early phase to understand how
label-free mirrors the innate complexity of drug-target
interactions in living cells or cell systems. To elucidate
biased agonism, several different approaches have been
proposed. Owing to wide pathway coverage, label free is
quickly realized to be able to manifest the biased agon-
ism through producing pathway-dependent variations in
the whole cell phenotypic profile of different ligands
[15]. Multi-parameter analysis based on kinetics can be
used to sort ligands into different clusters [13]. Profiling
of the same set of ligands in different cellular back-
grounds has been attempted to determine biased agon-
ism [52], while comparing label-free with molecular
assay results also manifests biased agonism within the
same cell background [53]. Controlling the duration of
agonist exposure and receptor resensitization using
microfluidics offers additional levers to determine ligand-
directed functional selectivity [54]. The iPOT approach
represents the next step toward deeper and broader eluci-
dation of the biological complexity of drug-target interac-
tions. This approach leverages the signaling capacity of a
receptor and the sensitivity of label-free profiles to cell
preconditioning via pathway modulation. Owing to the
same measurement (that is, the label-free profiling), simi-
larity analysis can be performed and used to sort ligands
into different clusters based on their ontarget and off-
target pharmacology. A rationale way for lead selection
based on the iPOT is to select a few representative ligands
from each cluster for in vivo testing. The future of label-
free is dependent on the identification of an in vitro label-
free profile that is linked to the in vivo action of drug
molecules. Nonetheless, the high resolution heat maps
and pharmacological characterization of the opioid recep-
tor family using DMR response assays suggest that the
iPOT is powerful new approach for elucidating of the
complex and multifaceted efficacy of GPCR ligands, and
label-free cellular assays are uniquely sensitive to the com-
plexities of receptor mediated signal transduction at the
whole-cell level, and as such inform the process of drug
discovery in ways that other assay technologies cannot.
The power of the iPOT to differentiate ligands can be fur-
ther improved by using optimizing the algorithm for simi-
larity analysis, in particular methods that take both time
domain and signal amplitude into account [35]. The iPOT
approach offers a unique platform for drug development
when functional selectivity is important.
Conclusions
In conclusion, we have applied label-free DMR whole
cell profile-centred iPOT approach to systematically sur-
vey a fifty-five ligand library against the opioid receptor
family members in both native and engineered cell back-
grounds. The off-target activity, binding and functional
selectivity of these ligands have been clearly evident.
Notable is that all ligands display certain agonist activity
under specific conditions, and opioid ligands exhibit
complex pharmacology in both receptor and cell back-
ground dependent manner. These label-free profiling re-
sults also suggest the necessity to reclassify the ligands.
The profiling approach presented here may be useful for
lead compound selection.
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